Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Profit After Tax (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Profit After Tax for 10 consecutive years, with -$47.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 9.73% to -$47.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$196.5 million, a 24.59% increase, with the full-year FY2025 number at -$196.5 million, up 24.58% from a year prior.
  • Profit After Tax was -$47.5 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$52.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $43.8 million in Q1 2021 to a low of -$141.4 million in Q1 2024.
  • A 5-year average of -$41.0 million and a median of -$43.9 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: soared 228.06% in 2021, then crashed 244.11% in 2022.
  • Rhythm Pharmaceuticals' Profit After Tax stood at $29.5 million in 2021, then plummeted by 244.11% to -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then dropped by 3.98% to -$43.3 million in 2024, then decreased by 9.73% to -$47.5 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Profit After Tax are -$47.5 million (Q4 2025), -$52.9 million (Q3 2025), and -$46.6 million (Q2 2025).